The filing is an advance notice of intent to sell by a significant institutional holder. Monitor whether the sale actually executes and if additional insider selling follows; the small size relative to market cap suggests limited immediate price impact.
VTVT drugs
VTVT drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $19.69entry
- T+1 · 21h ago −10.16%α −8.25% · $17.69
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Samsara BioCapital, L.P., a major shareholder, filed Form 144 to sell 61,287 shares of vTv Therapeutics common stock, with an estimated aggregate market value of approximately $1.32 million. The sale is planned for the open market, and the filing indicates the insider has considered selling a portion of its holdings.
Key Facts
- Samsara BioCapital, L.P. filed Form 144 to sell 61,287 shares of vTv Therapeutics common stock.
- Estimated aggregate market value of the proposed sale is $1,315,831.89.
- Shares were acquired through open market purchases, a private placement, and a warrant exercise.
- The sale is planned for the open market via Merrill Lynch.
- The filing date is November 12, 2026.
Financial Impact
Proposed sale of 61,287 shares valued at approximately $1.32 million, representing a small fraction of the company's market cap.
Risk Factors
- The sale may not occur; Form 144 is only an intent to sell.
- If executed, the sale could signal reduced conviction from a major shareholder, though the amount is modest.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-073518 |
| Document: 0001628280-26-073518-index.html | 0001628280-26-073518 |
| Document: 0001628280-26-073518.txt | 0001628280-26-073518 |
Track record
9 reports on VTVT
Filters
- Nov 16, 2026today SC 13D/A Neutral 3/10 Entry $17.69 Now $17.69 +0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 3/10 Viewing Entry $19.69 Now $17.69 −10.16% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $21.03 Now $17.69 −15.88% settles Dec 7
- Oct 8, 20265w ago SC 13G/A Neutral 3/10 Entry $31.18 to $21.03 Now $17.69 −43.26% ▼ −32.55% −26.99% vs SPY
- Jun 10, 202622w ago DEFA14A Neutral 3/10 Entry $31.59 to $33.44 Now $17.69 −44.00% ▲ +5.86% +3.97% vs SPY
- May 8, 202627w ago Press Release Neutral 2/10 Entry $30.46 to $31.77 Now $17.69 −41.92% ▲ +4.30% +4.61% vs SPY
- Mar 10, 202635w ago Press Release Mixed 6/10 Entry $35.10 to $37.30 Now $17.69 −49.60% ▲ +6.27% +5.74% vs SPY
- Feb 26, 202637w ago 8-K Neutral 4/10 Entry $39.32 to $37.80 Now $17.69 −55.01% ▼ −3.87% +2.54% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers